TITLE:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

CONDITION:
Anemia

INTERVENTION:
methoxy polyethylene glycol-epoetin beta [Mircera]

SUMMARY:

      This study will determine the appropriate dose and frequency of administration of iv Mircera
      maintenance therapy in hemodialysis patients with chronic renal anemia who were previously
      receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target
      sample size is <100 individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  chronic renal anemia;

          -  on hemodialysis therapy for at least 3 months;

          -  receiving iv epoetin alfa during the 2 weeks prior to the run-in period.

        Exclusion Criteria:

          -  women who are pregnant, breastfeeding or using unreliable birth control methods;

          -  use of any investigational drug within 30 days of the run-in phase, or during the
             run-in or study treatment period.
      
